-- Experienced Executive Will Strengthen Capabilities to
Reiter has more than 20 years of experience in the agriculture and food
industries. Most recently, Reiter was US country head for STK Bio-ag
Technologies, where she managed sales, distribution and business
development functions. She previously served in senior positions with
Throughout her career, Reiter has helped guide companies through significant strategic changes. She led AgraQuest’s commercial and marketing focus during a time of significant growth, launching four new products globally and more than doubling revenue. Later, after the company was acquired by Bayer, she introduced biological-based products to Bayer’s global crop science organization.
“Sarah is an outstanding leader with the business strategy and marketing experience we need to commercialize Arcadia’s products and technologies,” said Raj Ketkar, Arcadia’s president & CEO. “With her expertise, Arcadia will be able to bring our health and nutrition products to market and strengthen relationships with partners across the ag-food supply chain.”
“It is a very exciting time to join the Arcadia team in the midst of the pivotal expansion in their go-to-market strategy beyond agricultural input traits to branded nutritional ingredients,” said Reiter. “I look forward to helping steer the company through its strategic evolution and build the business for Arcadia’s high-value pipeline of innovative, consumer-driven products.”
Reiter holds a bachelor’s degree in English from the
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements are subject to risks and uncertainties that
could cause actual results to differ materially, and reported results
should not be considered as an indication of future performance. These
risks and uncertainties include, but are not limited to: the company’s
expectations of Sarah Reiter’s potential contributions as an executive
on the management team; and the other risks set forth in the company’s
filings with the
Arcadia Biosciences, Inc.
View printer-friendly version